Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 3839-3851

  Coen, N ^a   Singh, U ^b   Vuyyuru, V ^b   Van den Oord, J J ^c   Balzarini, J ^a   Duraffour, S ^a   Snoeck, R ^a   Cheng, Y C ^d   Chu, C K ^b   Andrei, G ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (HYDROXYMETHYL) 1,3 DIOXOLAN 4 YL] 5 VINYLPYRIMIDINE 2,4(1H,3H) DIONE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; ANTIVIRUS AGENT; PYRIMIDINE NUCLEOSIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG; USS 027144; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOMEGALOVIRUS; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; EPSTEIN BARR VIRUS; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; HERPES VIRUS SAIMIRI; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IN VITRO STUDY; IN VIVO STUDY; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RHADINOVIRUS; VARICELLA ZOSTER VIRUS; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; AOTIDAE; DNA PRIMERS; FIBROBLASTS; GAMMAHERPESVIRINAE; HUMANS; MACACA MULATTA; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; MUTATION; NIH 3T3 CELLS; NUCLEOSIDES; PYRIMIDINE NUCLEOSIDES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RHADINOVIRUS; SPECIES SPECIFICITY; STATISTICS, NONPARAMETRIC; THYMIDINE KINASE; VIRUS REPLICATION;

ANIMALIA; CERCOPITHECINE HERPESVIRUS 17; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 8; MURID HERPESVIRUS 4; MURINE HEPATITIS VIRUS; MUS; SAIMIRIINE HERPESVIRUS 2;

EID: 84876245507     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03338-12     Document Type: Article

References (58)

1. Roizman BD, Knipe M, Whitley J. 2007. Herpes simplex viruses, p 2501-2601. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Longnecker R, Neipel R. 2007. Introduction to the human gammaherpesviruses, p 341-359. In Arvin A, Campadelli-Fiume G, Macrski E, Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
3. Damania B. 2004. Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nat. Rev. Microbiol. 2:656-668.
4. Krueger H, Stuart A, Gallagher R, Williams A. 2010. HPV and other infectious agents in cancer. Oxford University Press, New York, NY.
5. Lei X, Bai Z, Ye F, Huang Y, Gao SJ. 2010. Regulation of herpesvirus lifecycle by viral microRNAs. Virulence 1:433-435.
6. Mocarski ES. 2007. Comparative analysis of herpesvirus-common proteins, p 44-58. In Arvin A, Campadelli-Fiume G, Macrski E, Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
7. Coen DM. 2009. Antiherpesviral DNA polymerase inhibitors, 1-18. In LaFamina R (ed), Antiviral research: strategies in antiviral drug discovery. ASM Press, Washington, DC.
8. Gilbert C, Bestman-Smith J, Boivin G. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5:88-114.
9. De Clercq E. 2004. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2:704-720.
10. Andrei G, Snoeck R. 2011. Emerging drugs for varicella-zoster virus infections. Expert. Opin. Emerg. Drugs 16:507-535.
11. Kimberlin DW, Whitley RJ. 2007. Antiviral therapy of HSV-1 and-2, p 1153-1174. In Arvin A, Campadelli-Fiume G, Macrski E, Moore PS, Roizman B, Whitley R, YamanishiK(ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
12. Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER. 2003. In vitro activities of benzimidazole D-and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47:2186-2192.
13. Casper C, Wald A. 2007. The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma. Curr. Top. Microbiol. Immunol. 312:289-307.
14. Gershburg E, Pagano JS. 2005. Epstein-Barr virus infections: prospects for treatment. J. Antimicrob. Chemother. 56:277-281.
15. Miller G, Heston L, Grogan E, Gradoville L, Rigsby M, Sun R, Shedd D, Kushnaryov VM, Grossberg S, Chang Y. 1997. Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J. Virol. 71:314-324.
16. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC. 2010. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J. Virol. 84:4534-4542.
17. Gershburg E, Pagano JS. 2008. Conserved herpesvirus protein kinases. Biochim. Biophys. Acta 1784:203-212.
18. Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD. 1998. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob. Agents Chemother. 42:2923-2931.
19. Tung PP, Summers WC. 1994. Substrate specificity of Epstein-Barr virus thymidine kinase. Antimicrob. Agents Chemother. 38:2175-2179.
20. Gustafson EA, Schinazi RF, Fingeroth JD. 2000. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J. Virol. 74:684-692.
21. Honess RW, O'Hare P, Young D. 1982. Comparison of thymidine kinase activities induced in cells productively infected with herpesvirus saimiri and herpes simplex virus. J. Gen. Virol. 58:237-249.
22. Wu CC, Chen MC, Chang YR, Hsu TY, Chen JY. 2004. Identification and characterization of the conserved nucleoside-binding sites in the Epstein-Barr virus thymidine kinase. Biochem. J. 379:795-803.
23. Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF. 1999. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J. Virol. 73:4786-4793.
24. Barnes A, Dyson H, Sunil-Chandra NP, Collins P, Nash AA. 1999. 2=-Deoxy-5-ethyl-beta-4=-thiouridine inhibits replication of murine gammaherpesvirus and delays the onset of virus latency. Antivir. Chem. Chemother. 10:321-326.
25. Neyts J, De Clercq E. 1998. In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents. Antimicrob. Agents Chemother. 42:170-172.
26. Pepper SD, Stewart JP, Arrand JR, Mackett M. 1996. Murine gammaherpesvirus-68 encodes homologues of thymidine kinase and glycoprotein H: sequence, expression, and characterization of pyrimidine kinase activity. Virology 219:475-479.
27. Sabini E, Hazra S, Konrad M, Lavie A. 2007. Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L-and D-nucleosides. J. Med. Chem. 50:3004-3014.
28. Cheng YC. 2001. Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers. Cancer Lett. 162(Suppl.):S33-S37.
29. Choi Y, Li L, Grill S, Gullen E, Lee CS, Gumina G, Tsujii E, Cheng YC, Chu CK. 2000. Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses. J. Med. Chem. 43:2538-2546.
30. Mathe C, Gosselin G. 2006. L-Nucleoside enantiomers as antivirals drugs: a mini-review. Antiviral Res. 71:276-281.
31. Lin JS, Kira T, Gullen E, Choi Y, Qu F, Chu CK, Cheng YC. 1999. Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein Barr virus agents. J. Med. Chem. 42:2212-2217.
32. Kira T, Grill SP, Dutschman GE, Lin JS, Qu F, Choi Y, Chu CK, Cheng YC. 2000. Anti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinase. Antimicrob. Agents Chemother. 44:3278-3284.
33. Andrei G, Balzarini J, Fiten P, De Clercq E, Opdenakker G, Snoeck R. 2005. Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin. J. Virol. 79:5863-5869.
34. Andrei G, Georgala A, Topalis D, Fiten P, Aoun M, Opdenakker G, Snoeck R. 11 January 2013. Heterogeneity and evolution of thymidine kinase andDNApolymerase mutants of herpes simplex virus type 1 (HSV-1): implications for antiviral therapy. J. Infect. Dis. [Epub ahead of print.] doi:10.1093/infdis/jit019.
35. Friedrichs C, Neyts J, Gaspar G, De Clercq E, Wutzler P. 2004. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res. 62:121-123.
36. Rochford R, Lutzke ML, Alfinito RS, Clavo A, Cardin RD. 2001. Kinetics of murine gammaherpesvirus 68 gene expression following infection of murine cells in culture and in mice. J. Virol. 75:4955-4963.
37. Flano E, Husain SM, Sample JT, Woodland DL, Blackman MA. 2000. Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J. Immunol. 165:1074-1081.
38. Sunil-Chandra NP, Efstathiou S, Arno J, Nash AA. 1992. Virological and pathological features of mice infected with murine gamma-herpesvirus 68. J. Gen. Virol. 73:2347-2356.
39. Sunil-Chandra NP, Efstathiou S, Nash AA. 1992. Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. J. Gen. Virol. 73:3275-3279.
40. Andrei G, De Clercq E, Snoeck R. 2009. Viral DNA polymerase inhibitors, p 481-526. In Cameron CE, Gotte M, Raney KD (ed), Viral genome replication. Springer Science, New York, NY.
41. Balasubramaniam NK, Veerisetty V, Gentry GA. 1990. Herpesviral deoxythymidine kinases contain a site analogous to the phosphorylbinding arginine-rich region of porcine adenylate kinase; comparison of secondary structure predictions and conservation. J. Gen. Virol. 71:2979-2987.
42. Wild K, Bohner T, Folkers G, Schulz GE. 1997. The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue. Protein Sci. 6:2097-2106.
43. Frobert E, Ooka T, Cortay JC, Lina B, Thouvenot D, Morfin F. 2005. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob. Agents Chemother. 49:1055-1059.
44. Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D. 2000. Genetic characterization of thymidine kinase from acyclovir-resistant and-susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J. Infect. Dis. 182:290-293.
45. Suzutani T, Lacey SF, Powell KL, Purifoy DJ, Honess RW. 1992. Random mutagenesis of the thymidine kinase gene of varicella-zoster virus. J. Virol. 66:2118-2124.
46. Suzutani T, Ishioka K, De CE, Ishibashi K, Kaneko H, Kira T, Hashimoto K, Ogasawara M, Ohtani K, Wakamiya N, Saijo M. 2003. Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir. Antimicrob. Agents Chemother. 47:1707-1713.
47. Black ME, Loeb LA. 1993. Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: analysis of selected mutants in vitro. Biochemistry 32:11618-11626.
48. Piret J, Boivin G. 2011. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 55:459-472.
49. Evans JS, Lock KP, Levine BA, Champness JN, Sanderson MR, Summers WC, McLeish PJ, Buchan A. 1998. Herpesviral thymidine kinases: laxity and resistance by design. J. Gen. Virol. 79:2083-2092.
50. Morfin F, Thouvenot D. 2003. Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 26:29-37.
51. Saijo M, Suzutani T, Niikura M, Morikawa S, Kurane I. 2002. Importance of C terminus of herpes simplex virus type 1 thymidine kinase for maintaining thymidine kinase and acyclovir-phosphorylation activities. J. Med. Virol. 66:388-393.
52. Gaudreau A, Hill E, Balfour HH, Jr, Erice A, Boivin G. 1998. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J. Infect. Dis. 178:297-303.
53. Balzarini J, Liekens S, Solaroli N, El OK, Stammers DK, Karlsson A. 2006. Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation. J. Biol. Chem. 281:19273-19279.
54. Flano E, Woodland DL, Blackman MA. 2002. A mouse model for infectious mononucleosis. Immunol. Res. 25:201-217.
55. Stewart JP, Usherwood EJ, Ross A, Dyson H, Nash T. 1998. Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J. Exp. Med. 187:1941-1951.
56. Tripp RA, Hamilton-Easton AM, Cardin RD, Nguyen P, Behm FG, Woodland DL, Doherty PC, Blackman MA. 1997. Pathogenesis of an infectious mononucleosis-like disease induced by a murine gammaherpesvirus: role for a viral superantigen? J. Exp. Med. 185:1641-1650.
57. Dittmer D, Stoddart C, Renne R, Linquist-Stepps V, Moreno ME, Bare C, McCune JM, Ganem D. 1999. Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice. J. Exp. Med. 190:1857-1868.
58. Parsons CH, Adang LA, Overdevest J, O'Connor CM, Taylor JR, Jr, Camerini D, Kedes DH. 2006. KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J. Clin. Invest. 116:1963-1973.